International Filing Date: January 28, 2005

US Application No: not yet assigned

Preliminary Amendment

Page 2 of 9

Attorney Docket No: 0279us310

Listing of Claims:

The following listing of claims replaces all prior versions and listings of claims in the application. Please note that "Original" claims refer to claims as presented in International Application PCT/DK2005/000070.

- 1. (Original) A method for screening or selecting cells expressing a desired level of a polypeptide, comprising:
- a) providing a plurality of cells each comprising an expression cassette comprising a first polynucleotide encoding the polypeptide, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide, a reporter peptide or an epitope tag downstream of the stop codon;
- b) cultivating the cells in the presence of a termination suppression agent under conditions that allow expression of the polypeptide; and
- c) selecting at least one cell expressing the polypeptide fused to a cell membrane anchoring peptide, a reporter peptide or an epitope tag.
- 2. (Original) A method for evaluating recombinant polypeptide expression in a population of cells, comprising:
- a) providing a plurality of cells each comprising an expression cassette comprising a first polynucleotide encoding a recombinant polypeptide, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide, a reporter peptide or an epitope tag downstream of the stop codon;
- b) cultivating the cells in the presence of a termination suppression agent under conditions that allow expression of a fusion protein comprising the recombinant polypeptide and the cell membrane anchoring peptide, reporter peptide or epitope tag; and
- c) sorting the cells to select at least one cell expressing the fusion protein at a desired level and/or with a desired uniformity.

International Filing Date: January 28, 2005

US Application No: not yet assigned

Preliminary Amendment

Page 3 of 9

Attorney Docket No: 0279us310

3. (Original) A method for screening or selecting at least one cell expressing a polypeptide with a desired binding affinity to a ligand from cells expressing a library of polypeptide variants, comprising:

- a) providing a plurality of cells each comprising an expression cassette comprising a first polynucleotide encoding a polypeptide variant, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide, a reporter peptide or an epitope tag downstream of the stop codon;
- b) cultivating the cells in the presence of a termination suppression agent under conditions that allow expression of the polypeptide variant; and
- c) selecting at least one cell expressing the polypeptide variant fused to a cell membrane anchoring peptide based on binding affinity of said polypeptide variant to said ligand.
- 4. (Amended) The method of <u>claim 1</u>-any of the preceding claims, wherein the termination suppression agent is an aminoglycoside antibiotic.
- 5. (Amended) The method of <u>claim 1</u>-any of the preceding claims, wherein the cells are screened or selected by FACS.
- 6. (Amended) The method of <u>claim 1</u> any of the preceding claims, wherein the second polynucleotide encodes a cell membrane anchoring peptide, and wherein the at least one selected cell expresses a fusion protein comprising the polypeptide fused to a cell membrane anchoring peptide, the fusion protein being displayed at the surface of said cell.

7. – 14. (Canceled)

15. (Amended) The method of <u>claim 1</u>-any of the preceding claims, further comprising:

International Filing Date: January 28, 2005

US Application No: not yet assigned

Preliminary Amendment

Page 4 of 9

Attorney Docket No: 0279us310

d) cultivating at least one selected cell in the absence of a termination suppression agent to obtain expression of the polypeptide as a soluble polypeptide.

- 16. (Original) A method for alternately expressing i) a soluble, untagged polypeptide or ii) a membrane-bound or tagged polypeptide from a single cell or cell line, comprising:
- a) providing a plurality of cells each comprising an expression cassette comprising a first polynucleotide encoding the polypeptide, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide, a reporter peptide or an epitope tag downstream of the stop codon;
- b) cultivating the cells in the presence of a termination suppression agent under conditions that allow expression of the polypeptide;
- c) selecting at least one cell expressing the polypeptide fused to a cell membrane anchoring peptide, a reporter peptide or an epitope tag; and
- d) cultivating said selected cell in the absence of a termination suppression agent to obtain expression of the polypeptide as a soluble polypeptide.
- 17. (Original) The method of claim 16, wherein the termination suppression agent is an aminoglycoside antibiotic.
- 18. (Amended) The method of claim 16-or-17, wherein the cells are screened or selected by FACS.
- 19. (Amended) The method of <u>claim 16 any of claims 16-18</u>, wherein the second polynucleotide encodes a cell membrane anchoring peptide, and wherein the at least one selected cell expresses a fusion protein comprising the polypeptide fused to a cell membrane anchoring peptide, the fusion protein being displayed at the surface of said cell.

20. - 27. (Canceled)

International Filing Date: January 28, 2005

US Application No: not yet assigned

Preliminary Amendment

Page 5 of 9

Attorney Docket No: 0279us310

- 28. (Original) A method for alternately expressing i) a membrane-bound, untagged polypeptide or ii) a membrane-bound, tagged polypeptide from a single cell or cell line, comprising:
- a) providing a plurality of cells each comprising an expression cassette comprising a first polynucleotide encoding the polypeptide and a cell membrane anchoring peptide, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a reporter peptide or an epitope tag downstream of the stop codon;
- b) cultivating the cells in the presence of a termination suppression agent under conditions that allow expression of the polypeptide and the cell membrane anchoring peptide;
- selecting at least one cell expressing a fusion protein comprising the
 polypeptide, the cell membrane anchoring peptide, and a reporter peptide or an epitope tag;
 and
- d) cultivating said selected cell in the absence of a termination suppression agent to obtain expression of a protein comprising the polypeptide in membrane-bound form without the reporter peptide or epitope tag.
- 29. (Original) The method of claim 28, wherein the termination suppression agent is an aminoglycoside antibiotic.
- 30. (Amended) The method of claim 28-or 29, wherein the cells are screened or selected by FACS.
- 31. 36. (Canceled)
- 37. (Original) A method for screening or selecting cells expressing a polypeptide of interest from a population of cells, comprising:
- a) transfecting a population of cells with an expression cassette comprising, in sequence, a gene of interest, at least one stop codon, and a cell targeting peptide, wherein the expression cassette does not comprise an antibiotic resistance gene;

International Filing Date: January 28, 2005

US Application No: not yet assigned

Preliminary Amendment

Page 6 of 9

Attorney Docket No: 0279us310

- b) cultivating the transfected population of cells in the presence of a termination suppression agent; and
- c) selecting at least one cell expressing the polypeptide fused to a cell targeting peptide.
- 38. (Original) The method of claim 37, wherein the cell targeting peptide is selected from the group consisting of cell membrane anchoring peptides, nuclear localization signals, signals targeting the polypeptide to a non-nuclear sub-cellular compartment, and cellular structures.
- 39. (Canceled)
- 40. (Amended) The method of <u>claim 37 any of claims 37 39</u>, wherein the termination suppression agent is an aminoglycoside antibiotic.
- 41. (Canceled)
- 42. (Amended) The method of <u>claim 37</u> any of claims 37-41, wherein the cells are screened or selected by FACS.
- 43. (Amended) The method of any of claim 37-claims 37-42, further comprising:
- d) cultivating at least one selected cell in the absence of a termination suppression agent to obtain expression of the polypeptide without the cell targeting peptide.
- 44. (Original) A method for screening or selecting cells expressing a polypeptide of interest from a population of cells, comprising:
- a) transfecting a population of cells with an expression cassette comprising, in sequence, a gene of interest, at least one stop codon, and an antibiotic resistance gene, wherein the antibiotic resistance gene provides resistance to a non-aminoglycoside antibiotic;

International Filing Date: January 28, 2005

US Application No: not yet assigned

Preliminary Amendment

Page 7 of 9

of calle in the nurseure of an

Attorney Docket No: 0279us310

- b) cultivating the transfected population of cells in the presence of an aminoglycoside antibiotic and the non-aminoglycoside antibiotic; and
- c) selecting at least one cell which is able to grow in the presence of the non-aminoglycoside antibiotic.

45. - 46. (Canceled)

- 47. (Amended) The method of <u>claim 44 any of claims 44 46</u>, wherein the cells are screened or selected by FACS.
- 48. (Amended) The method of claim 44 any of claims 44 47, further comprising:
- d) cultivating at least one selected cell in the absence of any antibiotic to obtain expression of the polypeptide without expression of the antibiotic resistance gene.

49. – 50. (Canceled)

- 51. (Original) A method for screening or selecting cell clones expressing a desired level of a polypeptide, comprising:
- a) providing a plurality of cells each comprising an expression cassette comprising a first polynucleotide encoding the polypeptide, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide encoding a cell membrane anchoring peptide, a reporter peptide or an epitope tag downstream of the stop codon;
- b) cultivating the cells under conditions that allow expression of the polypeptide; and
- c) selecting at least one cell clone expressing the polypeptide fused to a cell membrane anchoring peptide.
- 52. (Original) The method of claim 51, wherein the cells are cultivated in the absence of an aminoglycoside antibiotic.

International Filing Date: January 28, 2005

US Application No: not yet assigned

Preliminary Amendment

Page 8 of 9

Attorney Docket No: 0279us310

53. (Amended) The method of claim 51-or 52, wherein the cell membrane anchoring peptide is a GPI anchor.

- 54. (Amended) A method for producing a polypeptide, comprising cultivating a cell line obtained by the method of <u>claim 1</u> any of the preceding claims, wherein the cell line is cultivated in the absence of an aminoglycoside antibiotic to allow expression of the polypeptide, and isolating said polypeptide.
- 55. (Original) The method of claim 54, where the polypeptide is a soluble polypeptide that is secreted into a culture medium, and the polypeptide is isolated from said medium.
- 56. (Canceled)
- 57. (Amended) A kit for performing the method of claim 1 The kit of claim 56, comprising one or more of: (1) at least one kit component comprising an expression cassette as defined in any of claims 1-47 claim 1; a cell or expression vector comprising said expression cassette; an aminoglycoside antibiotic; or a composition comprising at least one such component; (2) instructions for practicing a method as defined in any of claims 1-47 claim 1, instructions for using any component identified in (1) or any composition of any such component; (3) a container for holding said at least one such component or composition, and (4) packaging materials.